Transcriptomics reveal a molecular signature in the progression of nonalcoholic steatohepatitis and identifies PAI‑1 and MMP‑9 as biomarkers in in vivo and in vitro studies
- Authors:
- Yao Zhao
- Mirensha Yakufu
- Chong Ma
- Baicai Wang
- Jianhua Yang
- Junping Hu
-
Affiliations: College of Pharmacy, Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830017, P.R. China - Published online on: November 28, 2023 https://doi.org/10.3892/mmr.2023.13138
- Article Number: 15
-
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA and Ikramuddin S: Nonalcoholic steatohepatitis: A review. JAMA. 323:1175–1183. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Llovet JM, Willoughby CE, Singal AG, Greten TF, Heikenwälder M, El-Serag HB, Finn RS and Friedman SL: Nonalcoholic steatohepatitis-related hepatocellular carcinoma: Pathogenesis and treatment. Nat Rev Gastroenterol Hepatol. 20:487–503. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L and Wymer M: Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 64:73–84. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J and Bugianesi E: Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 15:11–20. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, Yang H, Liu C, Kam LY, Tan XXE, et al: Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 5:739–752. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Farrell GC and Larter CZ: Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology. 43((2 Suppl 1)): S99–S112. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Younossi ZM: Non-alcoholic fatty liver disease-A global public health perspective. J Hepatol. 70:531–544. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Angulo P, Keach JC, Batts KP and Lindor KD: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 30:1356–1362. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Tarantino G, Crocetto F, Di Vito C, Creta M, Martino R, Pandolfo SD, Pesce S, Napolitano L, Capone D and Imbimbo C: Association of NAFLD and insulin resistance with non metastatic bladder cancer patients: A cross-sectional retrospective study. J Clin Med. 10:3462021. View Article : Google Scholar : PubMed/NCBI | |
|
Cotter TG and Rinella M: Nonalcoholic fatty liver disease 2020: The state of the disease. Gastroenterology. 158:1851–1864. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Le MH, Le DM, Baez TC, Wu Y, Ito T, Lee EY, Lee K, Stave CD, Henry L, Barnett SD, et al: Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol. 79:287–295. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, Tordjman J and Clement K: Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 56:1751–1759. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41:1313–1321. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Taylor RS, Taylor RJ, Bayliss S, Hagström H, Nasr P, Schattenberg JM, Ishigami M, Toyoda H, Wai-Sun Wong V, Peleg N, et al: Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Gastroenterology. 158:1611–1625.e12. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Makri E, Goulas A and Polyzos SA: Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Arch Med Res. 52:25–37. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Anstee QM, Reeves HL, Kotsiliti E, Govaere O and Heikenwalder M: From NASH to HCC: Current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 16:411–428. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Haas JT, Vonghia L, Mogilenko DA, Verrijken A, Molendi-Coste O, Fleury S, Deprince A, Nikitin A, Woitrain E, Ducrocq-Geoffroy L, et al: Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution. Nat Metab. 1:604–614. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bedossa P: Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential. Liver Int. 38 (Suppl 1):S64–S66. 2018. View Article : Google Scholar | |
|
Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F and Poynard T; LIDO Study Group, : Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 128:1898–1906. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, Hooker J, Sy E, Savides MT, Alquiraish MH, et al: Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 152:598–607.e2. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, et al: Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 149:389–397.e10. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, et al: The EASL-lancet liver commission: Protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet. 399:61–116. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, et al: The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 45:846–854. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Graupera I, Thiele M, Serra-Burriel M, Caballeria L, Roulot D, Wong GL, Fabrellas N, Guha IN, Arslanow A, Expósito C, et al: Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin Gastroenterol Hepatol. 20:2567–2576.e6. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Kjaergaard M, Lindvig KP, Thorhauge KH, Andersen P, Hansen JK, Kastrup N, Jensen JM, Hansen CD, Johansen S, Israelsen M, et al: Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol. 79:277–286. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Day JW and Rosenberg WM: The enhanced liver fibrosis (ELF) test in diagnosis and management of liver fibrosis. Br J Hosp Med (Lond). 79:694–699. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bolarin DM and Azinge EC: Biochemical markers, extracellular components in liver fibrosis and cirrhosis. Nig Q J Hosp Med. 17:42–52. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Boyle M, Tiniakos D, Schattenberg JM, Ratziu V, Bugianessi E, Petta S, Oliveira CP, Govaere O, Younes R, McPherson S, et al: Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Rep. 1:188–198. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wong VW, Adams LA, de Lédinghen V, Wong GL and Sookoian S: Noninvasive biomarkers in NAFLD and NASH-current progress and future promise. Nat Rev Gastroenterol Hepatol. 15:461–478. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Daniels SJ, Leeming DJ, Eslam M, Hashem AM, Nielsen MJ, Krag A, Karsdal MA, Grove JI, Neil Guha I, Kawaguchi T, et al: ADAPT: An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology. 69:1075–1086. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Harrison SA, Ratziu V, Boursier J, Francque S, Bedossa P, Majd Z, Cordonnier G, Sudrik FB, Darteil R, Liebe R, et al: A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: A prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 5:970–985. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC and McCullough AJ: Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology. 116:1413–1419. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Tatler AL: Recent advances in the non-invasive assessment of fibrosis using biomarkers. Curr Opin Pharmacol. 49:110–115. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Piazzolla VA and Mangia A: Noninvasive diagnosis of NAFLD and NASH. Cells. 9:10052020. View Article : Google Scholar : PubMed/NCBI | |
|
Govaere O, Cockell S, Tiniakos D, Queen R, Younes R, Vacca M, Alexander L, Ravaioli F, Palmer J, Petta S, et al: Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci Transl Med. 12:eaba44482020. View Article : Google Scholar : PubMed/NCBI | |
|
Castera L, Friedrich-Rust M and Loomba R: Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 156:1264–1281.e4. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Vilar-Gomez E and Chalasani N: Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 68:305–315. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hoang SA, Oseini A, Feaver RE, Cole BK, Asgharpour A, Vincent R, Siddiqui M, Lawson MJ, Day NC, Taylor JM, et al: Gene expression predicts histological severity and reveals distinct molecular profiles of nonalcoholic fatty liver disease. Sci Rep. 9:125412019. View Article : Google Scholar : PubMed/NCBI | |
|
Suppli MP, Rigbolt KTG, Veidal SS, Heebøll S, Eriksen PL, Demant M, Bagger JI, Nielsen JC, Oró D, Thrane SW, et al: Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. Am J Physiol Gastrointest Liver Physiol. 316:G462–G472. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Loomba R and Sanyal AJ: The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 10:686–690. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
European Association for the Study of Liver, . EASL clinical practical guidelines: Management of alcoholic liver disease. J Hepatol. 57:399–420. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Negi CK, Babica P, Bajard L, Bienertova-Vasku J and Tarantino G: Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism. 126:1549252022. View Article : Google Scholar : PubMed/NCBI | |
|
Abozaid YJ, Ayada I, van Kleef LA, Vallerga CL, Pan Q, Brouwer WP, Ikram MA, Van Meurs J, de Knegt RJ and Ghanbari M: Plasma proteomic signature of fatty liver disease: The rotterdam study. Hepatology. 78:284–294. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Ratziu V, Francque S and Sanyal A: Breakthroughs in therapies for NASH and remaining challenges. J Hepatol. 76:1263–1278. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Ramanan SP, Mohamed MWF, Aung SS, Sange I and Hamid P: Treatment of fatty liver disease: The present and the future. Cureus. 13:e127132021.PubMed/NCBI | |
|
Fu Y, Zhou Y, Shen L, Li X, Zhang H, Cui Y, Zhang K, Li W, Chen WD, Zhao S, et al: Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease. Front Pharmacol. 13:9733662022. View Article : Google Scholar : PubMed/NCBI | |
|
Hosseini-Esfahani F, Bahadoran Z, Mirmiran P, Hosseinpour-Niazi S, Hosseinpanah F and Azizi F: Dietary fructose and risk of metabolic syndrome in adults: Tehran lipid and glucose study. Nutr Metab (Lond). 8:502011. View Article : Google Scholar : PubMed/NCBI | |
|
Heikkinen S, Argmann CA, Champy MF and Auwerx J: Evaluation of glucose homeostasis. Curr Protoc Mol Biol Chapter. 29:Unit 29B.3. 2007.PubMed/NCBI | |
|
Love MI, Huber W and Anders S: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI | |
|
Yu G, Wang LG, Han Y and He QY: clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
McPherson S, Hardy T, Henderson E, Burt AD, Day CP and Anstee QM: Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. J Hepatol. 62:1148–1155. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Huang DQ, Terrault NA, Tacke F, Gluud LL, Arrese M, Bugianesi E and Loomba R: Global epidemiology of cirrhosis-aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 20:388–398. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Tarantino G, Balsano C, Santini SJ, Brienza G, Clemente I, Cosimini B and Sinatti G: It is high time physicians thought of natural products for alleviating NAFLD. Is there sufficient evidence to use them? Int J Mol Sci. 22:134242021.PubMed/NCBI | |
|
Santhekadur PK, Kumar DP and Sanyal AJ: Preclinical models of non-alcoholic fatty liver disease. J Hepatol. 68:230–237. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Eng JM and Estall JL: Diet-induced models of non-alcoholic fatty liver disease: Food for thought on sugar, fat, and cholesterol. Cells. 10:18052021. View Article : Google Scholar : PubMed/NCBI | |
|
Rinella ME and Green RM: The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol. 40:47–51. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lau JKC, Zhang X and Yu J: Animal models of non-alcoholic fatty liver disease: Current perspectives and recent advances. J Pathol. 241:36–44. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong F, Zhou X, Xu J and Gao L: Rodent models of nonalcoholic fatty liver disease. Digestion. 101:522–535. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JS, Jun DW, Kim EK, Jeon HJ, Nam HH and Saeed WK: Histologic and metabolic derangement in high-fat, high-fructose, and combination diet animal models. ScientificWorldJournal. 2015:3063262015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Z, Tian R, She Z, Cai J and Li H: Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 152:116–141. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Sveinbjornsson G, Ulfarsson MO, Thorolfsdottir RB, Jonsson BA, Einarsson E, Gunnlaugsson G, Rognvaldsson S, Arnar DO, Baldvinsson M, Bjarnason RG, et al: Multiomics study of nonalcoholic fatty liver disease. Nat Genet. 54:1652–1663. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Tincopa MA and Loomba R: Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol. 8:660–670. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Buzzetti E, Pinzani M and Tsochatzis EA: The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 65:1038–1048. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Naik A, Košir R and Rozman D: Genomic aspects of NAFLD pathogenesis. Genomics. 102:84–95. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Van De Craen B, Declerck PJ and Gils A: The biochemistry, physiology and pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. Thromb Res. 130:576–585. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ghosh AK and Vaughan DE: PAI-1 in tissue fibrosis. J Cell Physiol. 227:493–507. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Fuchs A, Samovski D, Smith GI, Cifarelli V, Farabi SS, Yoshino J, Pietka T, Chang SW, Ghosh S, Myckatyn TM and Klein S: Associations among adipose tissue immunology, inflammation, exosomes and insulin sensitivity in people with obesity and nonalcoholic fatty liver disease. Gastroenterology. 161:968–981.e12. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Verrijken A, Francque S, Mertens I, Prawitt J, Caron S, Hubens G, Van Marck E, Staels B, Michielsen P and Van Gaal L: Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 59:121–129. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Li Y, Liu N, Shen W, Xu W and Yao P: Identification of glucose metabolism-related genes in the progression from nonalcoholic fatty liver disease to hepatocellular carcinoma. Genet Res (Camb). 2022:85663422022. View Article : Google Scholar : PubMed/NCBI | |
|
Meng Q, Li X and Xiong X: Identification of Hub genes associated with non-alcoholic steatohepatitis using integrated bioinformatics analysis. Front Genet. 13:8725182022. View Article : Google Scholar : PubMed/NCBI | |
|
Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenwälder M and Tacke F: Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease-novel insights into cellular communication circuits. J Hepatol. 77:1136–1160. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Mittal R, Patel AP, Debs LH, Nguyen D, Patel K, Grati M, Mittal J, Yan D, Chapagain P and Liu XZ: Intricate functions of matrix metalloproteinases in physiological and pathological conditions. J Cell Physiol. 231:2599–2621. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hemmann S, Graf J, Roderfeld M and Roeb E: Expression of MMPs and TIMPs in liver fibrosis-a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol. 46:955–975. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Thieringer FR, Maass T, Anthon B, Meyer E, Schirmacher P, Longerich T, Galle PR, Kanzler S and Teufel A: Liver-specific overexpression of matrix metalloproteinase 9 (MMP-9) in transgenic mice accelerates development of hepatocellular carcinoma. Mol Carcinog. 51:439–448. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wagner J, Kumar Y, Lautenbach A, von Kroge P, Wolter S, Mann O, Izbicki J, Gagliani N and Duprée A: Fatty acid-binding protein-4 (FABP4) and matrix metalloproteinase-9 (MMP9) as predictive values for nonalcoholic steatohepatitis (NASH). Lipids Health Dis. 22:12023. View Article : Google Scholar : PubMed/NCBI | |
|
Goyale A, Jain A, Smith C, Papatheodoridi M, Misas MG, Roccarina D, Prat LI, Mikhailidis DP, Nair D and Tsochatzis E: Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. PLoS One. 16:e02603132021. View Article : Google Scholar : PubMed/NCBI | |
|
Kossakowska AE, Edwards DR, Lee SS, Urbanski LS, Stabbler AL, Zhang CL, Phillips BW, Zhang Y and Urbanski SJ: Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol. 153:1895–1902. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JW, Lee SH, Jeong SH, Kim H, Ahn KS, Cho JY, Yoon YS and Han HS: Increased urinary lipocalin-2 reflects matrix metalloproteinase-9 activity in chronic hepatitis C with hepatic fibrosis. Tohoku J Exp Med. 222:319–327. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bruschi F, D'Amato C, Piaggi S, Bianchi C, Castagna B, Paolicchi A and Pinto B: Matrix metalloproteinase (MMP)-9: A realiable marker for inflammation in early human trichinellosis. Vet Parasitol. 231:132–136. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Vandooren J, Van den Steen PE and Opdenakker G: Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade. Crit Rev Biochem Mol Biol. 48:222–272. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kim KE, Lee J, Shin HJ, Jeong EA, Jang HM, Ahn YJ, An HS, Lee JY, Shin MC, Kim SK, et al: Lipocalin-2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high-fat diet-fed Ob/Ob mice. Hepatology. 77:888–901. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Indira Chandran V, Wernberg CW, Lauridsen MM, Skytthe MK, Bendixen SM, Larsen FT, Hansen CD, Grønkjær LL, Siersbæk MS, Caterino TD, et al: Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness. Hepatology. 77:558–572. 2023. View Article : Google Scholar : PubMed/NCBI |
